Creative Planning Bei Gene, Ltd. Transaction History

Creative Planning

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Jul 20, 2018	SELL	$152.5 - $216.77 $381,707 - $542,575	-2,503 Closed	0 $0
Q1 2018 Apr 18, 2018	BUY	$97.41 - $177.22 $292 - $531	3 Added 0.12%	2,503 $421,000
Q3 2017 Oct 17, 2017	BUY	$66.19 - $103.46 $165,475 - $258,649	2,500	2,500 $259,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.1B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.